Financial Personal
Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum
Presentations at conferences will feature clinical data and business updates on Aurion Biotech’s allogeneic cell therapy AURN001 for the treatment of corneal endothelial diseases SEATTLE & CAMBRIDGE, Mass. & TOKYO — Aurion Biotech, wh
SEATTLE & CAMBRIDGE, Mass. & TOKYO -- Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it will present clinical data on its allogeneic cell therapy drug candidate, AURN001, at the 42 nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2024) to be held September 6-10, 2024 in Barcelona, Spain. Aurion Biotech also will present and participate in several panel discussions during the Ophthalmology Futures European Forum, which takes place September 5th in Barcelona. Read More
